In the AM7577 PDX model, IL3RA-ADC administered at 10 mg/kg intraperitoneally (i.p.)reduced tumor burden compared to the vehicle or isotype control ADC, as indicated by a decreased number of human CD45 (hCD45)/human IL3RA (hIL3RA)-positive cells in blood on day 56 (both p < 0.001; Figure 3A). This evidence concerns the gene IL3RA and neoplasm.